Former Executive Director of Preclinical Safety at Novartis, Klaus Peter Hoffmann, MD, PhD, Joins NDA Partners as Expert

ROCHELLE, Va., Sept. 18, 2019 /PRNewswire-PRWeb/ -- NDA Partners Chairman Carl Peck, MD, announced today that Klaus Peter Hoffmann, MD, PhD, a well-respected preclinical drug development expert with a focus in the cardiovascular and metabolic disease therapeutic areas, has joined the firm as an Expert Consultant.

Prior to joining NDA Partners, Dr. Hoffmann served as Executive Director of Preclinical Safety and Global Expert for Cardiovascular Safety at Novartis Pharmaceuticals Corp. and as the Proof of Research in Development/Global Head Safety Pharmacology at Novartis Pharma AG. In addition to his roles with Novartis, he served as the Head of Non-Clinical Drug Safety, Basel at Roche and as the Head of Research/Experimental Pharmacology at Sanofi. In his early career, Dr. Hoffmann served as the Principal Research Investigator at Sterling Winthrop and as National Research Council Senior Associate at the National Institute for Occupational Safety and Health in Cincinnati, Ohio. Dr. Hoffmann has also served as Director of the Institute of Industrial Toxicology and Professor of Toxicology at Martin Luther University in Halle, Germany.

"We are very pleased to welcome Dr. Hoffmann to NDA Partners," said Dr. Peck. "Dr. Hoffmann's expertise in preclinical drug development and toxicology will be an excellent resource for our drug development clients, especially those developing therapies for cardiovascular and metabolic diseases."

Dr. Hoffmann received his Doctor of Medicine and Diploma of Medicine from Martin Luther University in Halle, Germany. He has published more than 400 journal articles, book chapters, abstracts, and has served as a reviewer for numerous international pharmacology and toxicology journals. He is an active member of the Health and Environmental Sciences Institute (HESI) subcommittees on cardiac safety and proarrhythmia models.

About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.

Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
MartinEarle@ndapartners.com

SOURCE NDA Partners LLC